article thumbnail

Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test

MedCity News

The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications. The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test appeared first on MedCity News.

Leads 299
article thumbnail

Report: Chronic conditions lead to medical debt at all income levels

MedCity News

Chronic conditions cause medical debt in U.S. Medical debt has frequently been associated with cancer and, more recently, diabetes treatment, but there are other chronic conditions that contribute significantly to medical bills — such as heart disease, asthma, anxiety and lung disease.

Medical 311
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Revolutionizing Medical Training with Advanced Technology

Infuse Medical

In todays rapidly advancing healthcare landscape, the demands placed on medical professionals are greater than ever. With new medical devices, surgical techniques, and treatment protocols emerging constantly, the need for effective, efficient, and scalable training methods has become paramount. billion by 2025.

Training 130
article thumbnail

Forks in the road lead one medical expert to a ‘game changing’ liver treatment

PharmaVoice

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

Leads 279
article thumbnail

Commercial Drug Sourcing for Clinical Trials

The sourcing of commercial drugs for use in clinical trials either as a comparator, rescue or co-medication can be a complex process. Choosing the right partner with global sourcing, regulatory, quality and clinical packaging expertise can provide the necessary guidance to help sponsors successfully navigate these challenges.

article thumbnail

Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study

MedCity News

Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class. The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News.

Leads 305
article thumbnail

The 2025 Pharma Toolkit for Virtual Medical Education

Impetus Digital

Pharma-exclusive Webinar: The 2025 Pharma Toolkit for Virtual Medical Education About the webinar Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders. Transform your approach and lead the curve in training!

Education 110